23 September 2016
An innovative precision medicine approach has been shown to effectively slow down the time it takes for a tumour to grow back.
Conducted by the Gustave Roussy Cancer Campus in Paris, the study involved 1,110 advanced patients who had already tried three or more cancer therapies and had no other viable options left. Each had their genes mapped and their treatment tailored accordingly.
It was found that 199 out of the 1,110 patients lasted around 30 per cent longer - between five and 32 months - before their cancer started growing again, compared to any of the previous therapies the patients had tried.
Patients involved in this trial had a variety of different cancer types, including lung, breast, head and neck, prostate, bladder, bowel and stomach cancer. Potential faulty molecules were identified as possible treatment targets in 411 individuals.
Dr Christophe Massard, head of the early drug development multidisciplinary committee at Gustave Roussy, said: "The great thing about this is that it's not just for one type of cancer - patients with many different types of cancer could benefit from this in the future."
Posted by Edward Bartel
Health News is provided by Axonn Media in collaboration with Spire Healthcare. Please note that all copy above is ©Axonn Media and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.